4-Hydroxyderricin Isolated from the Sap of <i>Angelica keiskei</i> Koidzumi: Evaluation of Its Inhibitory Activity towards Dipeptidyl Peptidase-IV
<i>Angelica keiskei</i> sap is used as a blood-sugar reducer in Indonesia, however its molecular mechanism has not yet been explored. 4-hydroxyderricin (4-HD) is one of the major components extracted from <i>A. keiskei</i> sap. The aim of this work was to isolate 4-HD from th...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
MDPI AG,
2019-11-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | <i>Angelica keiskei</i> sap is used as a blood-sugar reducer in Indonesia, however its molecular mechanism has not yet been explored. 4-hydroxyderricin (4-HD) is one of the major components extracted from <i>A. keiskei</i> sap. The aim of this work was to isolate 4-HD from the sap of <i>A. keiskei</i> planted in Lombok, Indonesia, and to study in silico and in vitro mechanisms against dipeptidyl peptidase-IV (DPP-IV). The dried sap was submitted to liquid−liquid extraction using solvents with different polarity. Further purification processing was conducted using gradient elution column chromatography. The isolated compound was a yellowish powder, <i>m</i>/<i>z</i> 339.2215 [M + H]<sup>+</sup>, which was confirmed as 4-HD. Sitagliptin, a DPP-IV inhibitor, was employed as the positive control for both the in silico and in vitro studies. It was indicated that 4-HD interacts with Glu<sup>206</sup> and Phe<sup>357</sup>, important amino acid residues in the DPP-IV binding pocket. These interactions are similar to that of sitagliptin. The affinity of 4-HD (inhibition constant (Ki) = 3.99 μM) to DPP-IV is lower than that of sitagliptin (inhibition constant (Ki) = 0.17 μM). Furthermore, in vitro study showed that 4-HD inhibits DPP-IV (IC<sub>50</sub> = 81.44 μM) weaker than for sitagliptin (IC<sub>50</sub> = 0.87 μM). We concluded that 4- HD might have potential in inhibiting DPP-IV. However, by considering the polar interaction of sitagliptin with DPP-IV, a further structure modification of 4-HD, e.g., by introducing a polar moiety such as a hydroxyl group, might be needed to obtain stronger activity as a DPP-IV inhibitor. |
|---|---|
| Item Description: | 2218-0532 10.3390/scipharm87040030 |